Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Cell Cycle Deregulation in Pre-neoplasia: Case Study of Barrett’s Oesophagus

  • Chapter
  • First Online:
Cell Cycle Deregulation in Cancer

Part of the book series: Current Cancer Research ((CUCR))

  • 1118 Accesses

Abstract

Most solid tumours develop through a pre-invasive stage referred to as intra-epithelial neoplasia (IEN). The lag time between development of IEN and progression to fully fledged cancer would allow for chemoprevention or therapeutic interventions; however in most cases, IEN remains undetected and the exact mechanisms for progression remain unknown. Barrett’s oesophagus, the premalignant stage of oesophageal adenocarcinoma, is the perfect model to study IEN since the oesophagus is readily accessible by endoscopy and allows for temporal follow-up of patients. Like most IEN, Barrett’s oesophagus and associated dysplasia are characterized by an increase in proliferation and the expansion of the proliferative compartment. These features have been associated with an increased risk of progression to cancer. There is evidence of dysregulation of the G1/S and G2/M checkpoints which may be caused by an accumulation of abnormally expressed growth factors and oncogenes. Furthermore, the abnormally high level of duodeno-gastro-oesophageal acid reflux bathing the distal oesophagus contributes further to increasing proliferation. The real challenge for future research will be to identify causal events and to develop better diagnostic methods and therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D et al. (2000) Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92(16): 1316–1321.

    Article  PubMed  CAS  Google Scholar 

  • Barrett MT, Pritchard D, Palanca-Wessels C, Anderson J, Reid BJ, Rabinovitch PS (2003) Molecular phenotype of spontaneously arising 4 N (G2-tetraploid) intermediates of neoplastic progression in Barrett’s esophagus. Cancer Res 63(14): 4211–4217.

    PubMed  CAS  Google Scholar 

  • Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG et al. (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22(1): 106–109.

    Article  PubMed  CAS  Google Scholar 

  • Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G et al. (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111(2): 251–263.

    Article  PubMed  CAS  Google Scholar 

  • Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC et al. (1991) Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 51(20): 5766–5769.

    PubMed  CAS  Google Scholar 

  • Brito MJ, Filipe MI, Linehan J, Jankowski J (1995) Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett’s epithelium: biological and clinical variables. Int J Cancer 60(1): 27–32.

    Article  PubMed  CAS  Google Scholar 

  • BSG (2005) Guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus. http://www.bsg.org.uk

  • Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS et al. (2008) Cell Proliferation, Cell Cycle Abnormalities, and Cancer Outcome in Patients with Barrett’s Esophagus: a Long-term Prospective Study. Clin Cancer Res 14(21): 6988–6995.

    Article  PubMed  CAS  Google Scholar 

  • Chen LQ, Hu CY, Gaboury L, Pera M, Ferraro P, Duranceau AC (2001) Proliferative activity in Barrett’s esophagus before and after antireflux surgery. Ann Surg 234(2): 172–180.

    Article  PubMed  CAS  Google Scholar 

  • Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J (2006) Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett’s esophagus. Oncogene 25(21): 3084–3092.

    Article  PubMed  CAS  Google Scholar 

  • Coppola D, Schreiber RH, Mora L, Dalton W, Karl RC (1999) Significance of Fas and retinoblastoma protein expression during the progression of Barrett’s metaplasia to adenocarcinoma. Ann Surg Oncol 6(3): 298–304.

    Article  PubMed  CAS  Google Scholar 

  • DeLancey JO, Thun MJ, Jemal A, Ward EM (2008) Recent trends in Black-White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev 17(11): 2908–2912.

    Article  PubMed  Google Scholar 

  • Filipe MI, Jankowski J (1993) Growth factors and oncogenes in Barrett’s oesophagus and gastric metaplasia. Endoscopy 25(9): 637–641.

    Article  PubMed  CAS  Google Scholar 

  • Fitzgerald RC, Omary MB, Triadafilopoulos G (1996) Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 98(9): 2120–2128.

    Article  PubMed  CAS  Google Scholar 

  • Fitzgerald RC, Omary MB, Triadafilopoulos G (1998) Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett’s esophagus. Am J Physiol 275(1 Pt 1): G47–G55.

    PubMed  CAS  Google Scholar 

  • Fitzgerald RCOMB, Triadafilopoulos G (1996) Dynamic effects of acid on Barrett’s esophagus: an ex vivo proliferation and differentiation model. J Clin Investig 98(9): 2120–2127.

    Article  PubMed  CAS  Google Scholar 

  • Flejou JF, Paraf F, Muzeau F, Fekete F, Henin D, Jothy S et al. (1994) Expression of c-erbB-2 oncogene product in Barrett’s adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 47(1): 23–26.

    Article  PubMed  CAS  Google Scholar 

  • Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M (1987) Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327(6120): 298–303.

    Article  PubMed  CAS  Google Scholar 

  • Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH et al. (1999) Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5(8): 2121–2132.

    PubMed  CAS  Google Scholar 

  • Galiana C, Lozano JC, Bancel B, Nakazawa H, Yamasaki H (1995) High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog 14(4): 286–293.

    Article  PubMed  CAS  Google Scholar 

  • Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD et al. (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4(2): e67.

    Article  PubMed  CAS  Google Scholar 

  • Geddert H, Heep HJ, Gabbert HE, Sarbia M (2002a) Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer 94(1): 212–218.

    Article  PubMed  CAS  Google Scholar 

  • Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M (2002b) Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 118(1): 60–66.

    Article  PubMed  CAS  Google Scholar 

  • Gillen P, McDermott M, Grehan D, Hourihane DO, Hennessy TP (1994) Proliferating cell nuclear antigen in the assessment of Barrett’s mucosa. Br J Surg 81(12): 1766–1768.

    Article  PubMed  CAS  Google Scholar 

  • Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH (2002) Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett’s mucosa. Gut 50(3): 373–377.

    Article  PubMed  CAS  Google Scholar 

  • Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM et al. (2003) Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor. Gastroenterology 124(3): 615–625.

    Article  PubMed  CAS  Google Scholar 

  • Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D (1995) c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett’s oesophagus. J Clin Pathol 48(2): 129–132.

    Article  PubMed  CAS  Google Scholar 

  • Herbst JJ, Berenson MM, McCloskey DW, Wiser WC (1978) Cell proliferation in esophageal columnar epithelium (Barrett’s esophagus). Gastroenterology 75(4): 683–687.

    PubMed  CAS  Google Scholar 

  • Hong MK, Laskin WB, Herman BE, Johnston MH, Vargo JJ, Steinberg SM et al. (1995) Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus. Cancer 75(2): 423–429.

    Article  PubMed  CAS  Google Scholar 

  • Iftikhar SY, Steele RJ, Watson S, James PD, Dilks K, Hardcastle JD (1992) Assessment of proliferation of squamous, Barrett’s and gastric mucosa in patients with columnar lined Barrett’s oesophagus. Gut 33(6): 733–737.

    Article  PubMed  CAS  Google Scholar 

  • Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S et al. (1993) Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 71(10): 2902–2909.

    Article  PubMed  CAS  Google Scholar 

  • Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ (2009) A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology 136: 2101–2114.

    Article  PubMed  Google Scholar 

  • Jankowski J, Coghill G, Hopwood D, Wormsley KG (1992) Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33(8): 1033–1038.

    Article  PubMed  CAS  Google Scholar 

  • Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y et al. (2009) A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res 69(10): 4112–4115.

    Article  PubMed  CAS  Google Scholar 

  • Kaestner KH, Silberg DG, Traber PG, Schutz G (1997) The mesenchymal winged helix transcription factor Fkh6 is required for the control of gastrointestinal proliferation and differentiation. Genes Dev 11(12): 1583–1595.

    Article  PubMed  CAS  Google Scholar 

  • Kaur B, Omary M, Triadafilopoulos G (2000) Bile salt-induced cell proliferation in an ex vivo model of Barrett’s esophagus is associated with specific PKC isoform modulation. Am J Physiol Gastrointest Liver Physiol 278: G1000–G1009.

    PubMed  CAS  Google Scholar 

  • Kumble S, Omary MB, Cartwright CA, Triadafilopoulos G (1997) Src activation in malignant and premalignant epithelia of Barrett’s esophagus. Gastroenterology 112(2): 348–356.

    Article  PubMed  CAS  Google Scholar 

  • Lao-Sirieix P, Brais R, Lovat L, Coleman N, Fitzgerald RC (2004) Cell cycle phase abnormalities do not account for disordered proliferation in Barrett’s carcinogenesis. Neoplasia 6(6): 751–760.

    Article  PubMed  CAS  Google Scholar 

  • Lao-Sirieix P, Roy A, Worrall C, Vowler SL, Gardiner S, Fitzgerald RC (2006) Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 15(2): 288–293.

    Article  PubMed  CAS  Google Scholar 

  • Lord RV, O’Grady R, Sheehan C, Field AF, Ward RL (2000) K-ras codon 12 mutations in Barrett’s oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 15(7): 730–736.

    Article  PubMed  CAS  Google Scholar 

  • Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D et al. (2003) Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 125(2): 246–253.

    Article  PubMed  Google Scholar 

  • Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38(4): 468–473.

    Article  PubMed  CAS  Google Scholar 

  • Meltzer SJ, Zhou D, Weinstein WM (1989) Tissue-specific expression of c-Ha-ras in premalignant gastrointestinal mucosae. Exp Mol Pathol 51(3): 264–274.

    Article  PubMed  CAS  Google Scholar 

  • Morgan C, Alazawi W, Sirieix P, Freeman N, Coleman N, Fitzgerald RC (2003) Immediate and early gene response to in vitro acid exposure in a Barrett’s adenocarcinoma cell line. Gut 52(Suppl 1): A44.

    Google Scholar 

  • Naef AP, Savary M, Ozzello L (1975) Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 70(5): 826–835.

    PubMed  CAS  Google Scholar 

  • Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K et al. (1994) Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 73(7): 1785–1794.

    Article  PubMed  CAS  Google Scholar 

  • Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G et al. (1994) p53 mutations in Barrett’s adenocarcinoma and high-grade dysplasia. Gastroenterology 106(6): 1589–1595.

    PubMed  CAS  Google Scholar 

  • Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y et al. (2006) Impaired transforming growth factor beta signalling in Barrett’s carcinogenesis due to frequent SMAD4 inactivation. Gut 55(6): 764–774.

    Article  PubMed  CAS  Google Scholar 

  • Onwuegbusi BA, Rees JR, Lao-Sirieix P, Fitzgerald RC (2007) Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS One 2: e177.

    Article  PubMed  CAS  Google Scholar 

  • O’Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ et al. (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8(2): 314–346.

    PubMed  Google Scholar 

  • Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G (1999) Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 117(2): 327–335.

    Article  PubMed  CAS  Google Scholar 

  • Pabst O, Zweigerdt R, Arnold HH (1999) Targeted disruption of the homeobox transcription factor Nkx2-3 in mice results in postnatal lethality and abnormal development of small intestine and spleen. Development 126(10): 2215–2225.

    PubMed  CAS  Google Scholar 

  • Parrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J et al. (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 237(3): 291–298.

    Article  PubMed  Google Scholar 

  • Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL et al. (2008) p16 mutation spectrum in the premalignant condition Barrett’s esophagus. PLoS One 3(11): e3809.

    Article  PubMed  CAS  Google Scholar 

  • Pellish LJ (1980) HJAaeGL. Cell proliferation in three types of Barrett’s epithelium. Gut 21: 26–31.

    Article  PubMed  CAS  Google Scholar 

  • Persons DL, Croughan WS, Borelli KA, Cherian R (1998) Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 106(1): 11–17.

    Article  PubMed  CAS  Google Scholar 

  • Peters FTM, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CBHW et al. (1999) Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut 45(4): 489–494.

    Article  PubMed  CAS  Google Scholar 

  • Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ (2001) Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96(11): 3071–3083.

    Article  PubMed  CAS  Google Scholar 

  • Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS (1992) Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 102(4 Pt 1): 1212–1219.

    PubMed  CAS  Google Scholar 

  • Reid BJ, Sanchez CA, Blount PL, Levine DS (1993) Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105(1): 119–129.

    PubMed  CAS  Google Scholar 

  • Sancho E, Batlle E, Clevers H (2003) Live and let die in the intestinal epithelium. Curr Opin Cell Biol 15(6): 763–770.

    Article  PubMed  CAS  Google Scholar 

  • Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert HE (2001a) Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. Am J Clin Pathol 115(6): 835–840.

    Article  PubMed  CAS  Google Scholar 

  • Sarbia M, Bektas N, Muller W, Heep H, Borchard F, Gabbert HE (1999) Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer 86(12): 2597–2601.

    Article  PubMed  CAS  Google Scholar 

  • Sarbia M, Tekin U, Zeriouh M, Donner A, Gabbert HE (2001b) Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett’s oesophagus. Anticancer Res 21(1A): 387–392.

    PubMed  CAS  Google Scholar 

  • Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y et al. (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 24(25): 4138–4148.

    PubMed  CAS  Google Scholar 

  • Sciallero S, Giaretti W, Bonelli L, Geido E, Rapallo A, Conio M et al. (1993) DNA content analysis of Barrett’s esophagus by flow cytometry. Endoscopy 25(9): 648–651.

    Article  PubMed  CAS  Google Scholar 

  • Sirieix PS, O’Donovan M, Brown J, Save V, Coleman N, Fitzgerald RC (2003) Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett’s esophagus. Clin Cancer Res 9(7): 2560–2566.

    PubMed  CAS  Google Scholar 

  • Souza RF, Morales CP, Spechler SJ (2001) Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett’s oesophagus. Aliment Pharmacol Ther 15(8): 1087–1100.

    Article  PubMed  CAS  Google Scholar 

  • Souza RF, Shewmake K, Terada LS, Spechler SJ (2002) Acid exposure activates the mitogen-activated protein kinase pathways in Barrett’s esophagus. Gastroenterology 122(2): 299–307.

    Article  PubMed  CAS  Google Scholar 

  • Trautmann B, Wittekind C, Strobel D, Meixner H, Keymling J, Gossner L et al. (1996) K-ras point mutations are rare events in premalignant forms of Barrett’s oesophagus. Eur J Gastroenterol Hepatol 8(8): 799–804.

    PubMed  CAS  Google Scholar 

  • Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT et al. (2003) Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52(2): 174–180.

    Article  PubMed  CAS  Google Scholar 

  • Walch A, Bink K, Gais P, Stangl S, Hutzler P, Aubele M et al. (2000) Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett’s adenocarcinoma. Anal Cell Pathol 20(1): 25–32.

    PubMed  CAS  Google Scholar 

  • Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M et al. (2001) Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett’s esophagus. Lab Invest 81(6): 791–801.

    PubMed  CAS  Google Scholar 

  • Wang KK, Sampliner RE (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 103: 788–797.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Cell Unit, Hutchison-MRC Research Centre, Cambridge, CB2 0XZ, UK

    Pierre Lao-Sirieix & Rebecca C. Fitzgerald

Authors
  1. Pierre Lao-Sirieix
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca C. Fitzgerald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Lao-Sirieix .

Editor information

Editors and Affiliations

  1. Dept. Medicine, Fox Chase Cancer Center, Cottman Ave. 333, Philadelphia, 19111-2497, Pennsylvania, USA

    Greg H. Enders

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lao-Sirieix, P., Fitzgerald, R.C. (2010). Cell Cycle Deregulation in Pre-neoplasia: Case Study of Barrett’s Oesophagus. In: Enders, G. (eds) Cell Cycle Deregulation in Cancer. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1770-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1770-6_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1769-0

  • Online ISBN: 978-1-4419-1770-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation